The FDA approves Levaquin (levofloxacin), a fluoroquinolone antibiotic, for treating various bacterial infections, but Not specifically for Lyme disease. While doctors might prescribe it off-label in certain situations, this is not a standard treatment.
Off-Label Use Considerations
The Infectious Diseases Society of America (IDSA) guidelines recommend doxycycline or amoxicillin as first-line treatments for early Lyme disease. Ceftriaxone or cefotaxime are preferred for late-stage Lyme disease or neuroborreliosis. Levaquin’s use is generally reserved for patients who cannot tolerate or have allergic reactions to these preferred antibiotics. Careful consideration of potential risks is necessary given the fluoroquinolone class’s known side effects.
Potential Side Effects and Risks
Fluoroquinolones like Levaquin carry a risk of serious side effects, including tendonitis, tendon rupture, peripheral neuropathy, and central nervous system effects. These risks must be carefully weighed against the potential benefits, particularly in Lyme disease where alternative treatments exist. Detailed patient discussions regarding benefits and potential harms are crucial before prescribing.
